<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="76256">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02112877</url>
  </required_header>
  <id_info>
    <org_study_id>STE-HUM-004P</org_study_id>
    <secondary_id>STE-HUM-007P</secondary_id>
    <nct_id>NCT02112877</nct_id>
  </id_info>
  <brief_title>VIRTUS: An Evaluation of the Veniti Vici™ Venous Stent System in Patients With Chronic Iliofemoral Venous Outflow Obstruction</brief_title>
  <acronym>VIRTUS</acronym>
  <official_title>VIRTUS-OUS Safety and Efficacy of the Veniti Vici™ Venous Stent System (Veniti, Inc.) When Used to Treat Clinically Significant Chronic Non-malignant Obstruction of the Iliofemoral Venous Segment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Veniti</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Veniti</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, prospective, single arm, non-randomized study to evaluate safety and
      efficacy of the Veniti Vici™ Venous Stent System in relation to pre-defined Objective
      Performance goals. The follow-up period is 60 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this prospective study is to assess the safety and efficacy of the Veniti
      Vici™ Venous Stent System in achieving patency of the target venous lesion in patients with
      clinically significant chronic non-malignant obstruction of the iliofemoral venous outflow
      tract.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Safety Endpoint</measure>
    <time_frame>30 days</time_frame>
    <description>Major Adverse Events within 30 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Efficacy Endpoint</measure>
    <time_frame>12 months post-intervention</time_frame>
    <description>Primary patency rate</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Chronic Venous Disorder</condition>
  <condition>Venous Outflow Obstruction</condition>
  <condition>Symptomatic Venous Outflow Obstruction of Iliofemoral Vein</condition>
  <arm_group>
    <arm_group_label>Veniti Vici™ Venous Stent System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Veniti Vici™ Venous Stent System</intervention_name>
    <arm_group_label>Veniti Vici™ Venous Stent System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria - Pre-Procedure Criteria:

          -  Age ≥ 18 years

          -  Willing and capable of complying with all follow-up evaluations at the specified
             times

          -  Able and willing to provide written informed consent prior to study-specific
             procedures

          -  Presence of unilateral, clinically significant, chronic non-malignant obstruction of
             the common femoral vein, external iliac vein, common iliac vein, or any combination
             thereof, defined as a ≥50% reduction in target vessel lumen diameter (to be measured
             by venogram during procedure)

          -  Clinically significant venous obstruction defined as meeting at least one of the
             following clinical indicators:

               -  Clinical severity class of CEAP classification ≥3

               -  VCSS Pain Score ≥2

          -  Negative pregnancy test in females of child-bearing potential

          -  Intention to stent the target lesion only with the Veniti Vici Venous Stent

        Exclusion Criteria - Pre-Procedure Criteria:

          -  Presence or history of clinically significant pulmonary emboli within 6 months prior
             to enrollment.

          -  Venous obstruction that extends into the inferior vena cava (IVC)

          -  Contralateral disease of the common femoral vein, external iliac vein, common iliac
             vein, or any combination thereof with planned treatment within 30 days after subject
             enrollment

          -  Life expectancy &lt;12 months

          -  Female of childbearing potential who is pregnant or plans to become pregnant during
             the duration of the clinical study

          -  Uncontrolled or active coagulopathy OR known, uncorrectable bleeding diathesis with
             the following definitions:

               -  Uncorrected INR ≥2.0 or aPTT ≥1.5 X normal local lab value

               -  Platelet count &lt;80,000

          -  Uncorrected hemoglobin of ≤ 9 g/dL

          -  Patients with an estimated glomerular filtration rate (eGFR) &lt;30 mL/min. In patients
             with diabetes mellitus, eGFR &lt;45 mL/min.

          -  Known hypersensitivity to nickel or titanium

          -  Contrast agent allergy that cannot be managed adequately with pre-medication

          -  Intended concurrent thrombolysis or thrombectomy procedure OR intended or planned
             (within 30 days) adjuvant procedure such as creation of temporary arteriovenous
             fistula, placement of IVC filter, endovenectomy or saphenous vein ablation

          -  Current or recent (within 30 days) active participation in another drug or device
             clinical trial (Participation in observational studies is acceptable.)

          -  Patient judged to be a poor candidate by the primary investigator

          -  Patients who have had any prior surgical or endovascular procedure of the target
             vessel [Note: Patients who have had catheter-directed or mechanical thrombolysis in
             the target vessel for DVT at least 3 month (90 days) prior to the VIRTUS index
             procedure may be included in the trial.]

        Exclusion Criteria - Intra-Procedural Criteria:

          -  Patients in whom the lesions cannot be traversed with a guide wire.

          -  Patients where the obstruction extends into the inferior vena cava or below the level
             of the lesser trochanter.

          -  Patients whose vein diameters are not within limits stated in current Instructions
             for Use as determined by venogram.

          -  Patients who do not meet the venogram binary stenosis definition, as determined by
             the treating physician.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Marston, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNC Department of Surgery</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mahmood Razavi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vascular and Interventional Specialists of Orange County</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Heart Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marelene Muller</last_name>
      <phone>602-604-5211</phone>
      <email>mare.muller@abrazohealth.com</email>
    </contact>
    <contact_backup>
      <last_name>Patty Ames</last_name>
      <email>pames@abrazohealth.com</email>
    </contact_backup>
    <investigator>
      <last_name>Patricia Thorpe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arkansas Heart</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Gordon</last_name>
      <phone>501-748-8421</phone>
      <email>matthew.gordon@arheart.com</email>
    </contact>
    <investigator>
      <last_name>Vasili Lendel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA Dept. of Vascular Surgery</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lesley Sim</last_name>
      <phone>310-825-5825</phone>
      <email>LSim@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Brian DeRubertis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph Hospital Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandy Chung</last_name>
      <phone>714-744-8795</phone>
      <email>sandy.chung@stjoe.org</email>
    </contact>
    <investigator>
      <last_name>Mahmood Razavi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radiology Imaging Associates</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Talley</last_name>
      <phone>720-493-3403</phone>
      <email>Tiffany.Talley@riaco.com</email>
    </contact>
    <contact_backup>
      <last_name>Ashley Bitner</last_name>
      <phone>(720) 493-3403</phone>
      <email>Ashley.Bitner@riaco.com</email>
    </contact_backup>
    <investigator>
      <last_name>Brooke Spencer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vascular Breakthroughs</name>
      <address>
        <city>Darien</city>
        <state>Connecticut</state>
        <zip>06820</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liz Gagne</last_name>
      <phone>203-912-3227</phone>
      <email>epgagne@optonline.net</email>
    </contact>
    <contact_backup>
      <last_name>Maria Mylinski</last_name>
      <email>mmyslinski@thevascularexperts.com</email>
    </contact_backup>
    <investigator>
      <last_name>Paul Gagne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Fugal</last_name>
      <phone>203-785-4855</phone>
      <email>patricia.fugal@yale.edu</email>
    </contact>
    <investigator>
      <last_name>John Aruny, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center, Miami</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Florida Hospital, CV Research</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Midwest Cardiovascular Foundation - Genesis Medical Center</name>
      <address>
        <city>Davenport</city>
        <state>Iowa</state>
        <zip>52803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Christensen</last_name>
      <phone>563-324-4384</phone>
      <phone_ext>*Option 1</phone_ext>
      <email>christensenl@mcrfmd.com</email>
    </contact>
    <investigator>
      <last_name>Nicolas Shammas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Luke's Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margie Miller</last_name>
      <phone>816-932-9862</phone>
      <email>m2miller@saint-lukes.org</email>
    </contact>
    <contact_backup>
      <last_name>Cheryl Rutherford</last_name>
      <phone>(816) 932-9862</phone>
      <email>cjrutherford@saint-lukes.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jason Lindsey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vein Center of Louisiana - Christus St. Patrick's Hospital</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <zip>70601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DeeAnn Winey-Ward</last_name>
      <phone>337-312-8405</phone>
      <email>dwiney@imperialhealth.com</email>
    </contact>
    <contact_backup>
      <last_name>Justin Trahan</last_name>
      <phone>337-312-8413</phone>
      <email>JTrahan2@imperialhealth.com</email>
    </contact_backup>
    <investigator>
      <last_name>Carl Fastabend, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abdulah Hanifi</last_name>
      <phone>617-643-1372</phone>
      <email>AHANIFI@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Schainfeld, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Michigan Vascular Center</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maureen Blewett</last_name>
      <phone>810-600-2009</phone>
      <email>maureena@michiganvascular.com</email>
    </contact>
    <investigator>
      <last_name>Christopher Goltz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Vascular Group, PLLC</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryan Kaim</last_name>
      <phone>518-218-0148</phone>
      <email>KaimR@mail.amc.edu</email>
    </contact>
    <investigator>
      <last_name>Kathleen Ozsvath, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Taggert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacqueline Bott</last_name>
      <phone>212-263-2268</phone>
      <email>Jacqueline.Bott@nyumc.org</email>
    </contact>
    <investigator>
      <last_name>Mikel Sadek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mt. Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ellen Weiss</last_name>
      <phone>212-241-9369</phone>
      <email>ellen.weiss@mountsinai.org</email>
    </contact>
    <investigator>
      <last_name>Robert Lookstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Windsor Ting, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital/Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie Stern</last_name>
      <phone>212-746-9748</phone>
      <email>jas2071@med.cornell.edu;</email>
    </contact>
    <investigator>
      <last_name>Ronald Winokur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolle Lemire</last_name>
      <phone>919-843-1279</phone>
      <email>nicolle_lemire@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Raghuveer Vallabhaneni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Cepullio</last_name>
      <phone>412-623-8486</phone>
      <email>cepullioed@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Singh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr. Ediberto Soto-Cora's Office</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79925</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peggy Jamie</last_name>
      <phone>915-525-1243</phone>
      <email>pjaime.elpasoresearch@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ediberto Soto-Cora, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sentara Norfolk General Hospital</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23452</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janice Devlin</last_name>
      <phone>757-388-5629</phone>
      <email>jldevlin@sentara.com</email>
    </contact>
    <investigator>
      <last_name>David Dexter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miriam Silva</last_name>
      <phone>206-221-7833</phone>
      <email>silvacm8@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Meissner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Infermerierie Protestante</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phillipe Nicolini, MD</last_name>
      <phone>334 72 05 79 00</phone>
      <email>phnicolini@wanadoo.fr</email>
    </contact>
    <investigator>
      <last_name>Phillipe Nicolini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord</name>
      <address>
        <city>Marsaille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Didier Sanchez</last_name>
      <email>Didier.sanchez@ap-hm.fr</email>
    </contact>
    <contact_backup>
      <last_name>Elodie Hughes</last_name>
      <phone>00 334 91 43 53 75</phone>
      <email>elodie.hughes@ap-hm.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Oliver Hartung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Arnsberg, Karolinen Hospital</name>
      <address>
        <city>Arnsberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simmone Mueller</last_name>
      <phone>0049 0173 173 00 88</phone>
      <email>si.mueller@studynurse-si.de</email>
    </contact>
    <investigator>
      <last_name>Michael Lichtenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Galway</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Collette Kirwan</last_name>
      <phone>+353 91 494280</phone>
      <email>collette.kirwan@nuigalway.ie</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Daly</last_name>
      <phone>+353 91 495892</phone>
      <email>lisa.daly@nuigalway.ie</email>
    </contact_backup>
    <investigator>
      <last_name>Gerry O'Sullivan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rijnstate Ziekenhuis</name>
      <address>
        <city>Arnhem</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanne Holewijn</last_name>
      <phone>06-23681940</phone>
      <email>SHolewijn@rijnstate.nl</email>
    </contact>
    <investigator>
      <last_name>Michel Reijnen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Monteprincipe</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noelia Crespo</last_name>
      <phone>0034 657318916</phone>
      <email>ncrespo@hmhospitales.com</email>
    </contact>
    <investigator>
      <last_name>Luis Izquierdo-Lamoca, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas' Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Clark</last_name>
      <phone>020 8725 0892</phone>
      <email>Susan.Clark2@gstt.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Stephen Black, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Chen</last_name>
      <phone>0044 7810 445772</phone>
      <email>amanda.sf.cheng@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Toby Richards, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 13, 2017</lastchanged_date>
  <firstreceived_date>April 10, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>iliofemoral vein</keyword>
  <keyword>venous</keyword>
  <keyword>venous obstruction</keyword>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
